| pubmed-article:10385249 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10385249 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:10385249 | lifeskim:mentions | umls-concept:C0014822 | lld:lifeskim |
| pubmed-article:10385249 | lifeskim:mentions | umls-concept:C1801960 | lld:lifeskim |
| pubmed-article:10385249 | lifeskim:mentions | umls-concept:C0264995 | lld:lifeskim |
| pubmed-article:10385249 | lifeskim:mentions | umls-concept:C0036974 | lld:lifeskim |
| pubmed-article:10385249 | lifeskim:mentions | umls-concept:C0277785 | lld:lifeskim |
| pubmed-article:10385249 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:10385249 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:10385249 | pubmed:dateCreated | 1999-10-15 | lld:pubmed |
| pubmed-article:10385249 | pubmed:abstractText | 1. We investigated the effects of recombinant human erythropoietin (rh-EPO) in splanchnic artery occlusion (SAO) shock. Sham operated animals were used as controls. Survival rate, mean arterial blood pressure (MAP), serum Tumor Necrosis Factor (TNF-alpha), plasma nitrite/nitrate concentrations, red blood cell (RBC) count, blood haemoglobin (Hb), the responsiveness of aortic rings to phenylephrine (PE, 1 nM-10 microM) and the activity of inducible nitric oxide synthase (iNOS) were studied. 2. SAO shocked rats had a decreased survival rate (0% at 4 h of reperfusion, while sham shocked rats survived more than 4 h), enhanced serum TNF-alpha concentrations, increased plasma nitrite/nitrate levels (60+/-9.5 microM; sham shocked rats= 2+/-0.4 microM), decreased MAP, unchanged RBC count and blood Hb and enhanced iNOS activity in the aorta. Moreover aortic rings from shocked rats showed a marked hyporeactivity to PE. 3. Rh-EPO (25, 50 and 100 U 100 g(-1), 5 min following the onset of reperfusion) increased survival rate (70% at 4 h of reperfusion with the highest dose), reduced plasma nitrite/nitrate concentrations (10.3+/-3.3 microM), increased MAP, did not change RBC count and blood Hb, and inhibited iNOS activity in thoracic aortae. Furthermore rh-EPO, either in vivo or in vitro (10 U for 1 h in the organ bath), restored to control values the hyporeactivity to PE. Finally rh-EPO inhibited the activity of iNOS in peritoneal macrophages activated with endotoxin. 4. Our data suggest that rh-EPO protects against SAO shock by inhibiting iNOS activity. | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10385249 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10385249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10385249 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10385249 | pubmed:month | May | lld:pubmed |
| pubmed-article:10385249 | pubmed:issn | 0007-1188 | lld:pubmed |
| pubmed-article:10385249 | pubmed:author | pubmed-author:CaputiA PAP | lld:pubmed |
| pubmed-article:10385249 | pubmed:author | pubmed-author:SquadritoGG | lld:pubmed |
| pubmed-article:10385249 | pubmed:author | pubmed-author:SaittaAA | lld:pubmed |
| pubmed-article:10385249 | pubmed:author | pubmed-author:AltavillaDD | lld:pubmed |
| pubmed-article:10385249 | pubmed:author | pubmed-author:SquadritoFF | lld:pubmed |
| pubmed-article:10385249 | pubmed:author | pubmed-author:CampoG MGM | lld:pubmed |
| pubmed-article:10385249 | pubmed:author | pubmed-author:QuartaroneCC | lld:pubmed |
| pubmed-article:10385249 | pubmed:author | pubmed-author:ArlottaMM | lld:pubmed |
| pubmed-article:10385249 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10385249 | pubmed:volume | 127 | lld:pubmed |
| pubmed-article:10385249 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10385249 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10385249 | pubmed:pagination | 482-8 | lld:pubmed |
| pubmed-article:10385249 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:meshHeading | pubmed-meshheading:10385249... | lld:pubmed |
| pubmed-article:10385249 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10385249 | pubmed:articleTitle | Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. | lld:pubmed |
| pubmed-article:10385249 | pubmed:affiliation | Institute of Pharmacology, School of Medicine, University of Messina, Italy. squadrito@csnet.it | lld:pubmed |
| pubmed-article:10385249 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10385249 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:10385249 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10385249 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10385249 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10385249 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10385249 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10385249 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10385249 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10385249 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10385249 | lld:pubmed |
